Outlook Therapeutics (OTLK)Director bought ~$50K

~$50K

Approx. value · 122K sh @ $0.4093

126K

Holds after · shares reported

Traded

May 27, 2026

Filed

May 27, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 22, 2026Company filing · Form 8-K · Unregistered shares, Other newsSold new shares without registering them, and reported other company news
2. May 12, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
3. May 15, 2026Company filing · Form 8-K · ResultsReported its results
4. May 26, 2026Insider · 3 peopleInsiders: 3 purchases (~$194K)
5. May 27, 2026 · this disclosureInsider · 4 insiders in a week, 2nd time since 2016Director purchased ~$50K of OTLK shares in the open market

What came next

1. May 28, 2026Insider · 5 insiders in a week, 2nd time since 2016Director purchased ~$5M of OTLK shares in the open market
2. Jun 2, 2026Insider · 3 insiders in a week, 5th time since 2016Director purchased ~$24K of OTLK shares in the open market
3. Jun 26, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously reported, on February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq staff had determined to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”) from the Nasdaq Capital Market because it…”
4. Jul 16, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
5. Jul 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 21, 2026, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Outlook Therapeutics, Inc. (the “Company”) approved the grant of stock options to purchase shares of the Company’s common stock to the Company’s named executive officers as follows: Robert C. Jahr, the Company’s Chief Executive Officer – 100,000 options and Lawrence A. Kenyon, the Company’s Chief Financial…”
6. Jul 29, 2026Insider · 14 days before resultsDirector purchased ~$100K of OTLK shares in the open market
7. Aug 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
8. Aug 12, 2026Insider · 11 days before an 8-KDirector purchased ~$2.5M of OTLK shares in the open market
9. Aug 14, 2026Company filing · Form 8-K · ResultsReported its results
10. Aug 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 23, 2026, Outlook Therapeutics, Inc. (the “Company”) and Lawrence A. Kenyon, the Company’s Chief Financial Officer, Treasurer and Corporate Secretary and a member of the Company’s Board of Directors (the “Board”), mutually agreed that Mr. Kenyon would cease serving in the roles of Chief Financial Officer, Treasurer, Corporate Secretary, principal financial officer and principal accounting officer,…”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Outlook Therapeutics

For Outlook Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OTLK page.

Other recent filings by Faisal Ghiath Sukhtian, Director

• SEC Form 4 at Outlook Therapeutics (OTLK)Jul 29, 2026

The full history of Faisal Ghiath Sukhtian, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Outlook Therapeutics

• SEC Form 4Aug 14, 2026
• SEC Form 4Jul 29, 2026
• SEC Form 4Jun 3, 2026
• SEC Form 4Jun 2, 2026
• SEC Form 4May 27, 2026
• SEC Form 4May 27, 2026

Everything OQRO holds on this company is on its OTLK page.